According to the agreement filed with the SEC, ICON shares in the revenue stream for each and every test performed. Gerald mentioned in one of the conference calls after the announcement that the more tests ICON runs through their labs, the more money they make, so it benefits them to promote the test. Whether they are actively doing that, I can't answer, but it is reasonable to believe that if promoting the LymPro test leads to more tests arriving in the labs and higher ICON revenues, then they would promote the test, possibly in avenues other than those Amarantus in which is promoting.